UNSPSC 51431612: Pargyline hydrochloride

This classification denotes a monoamine oxidase inhibitor and antihypertensive agent with the molecular formula C11H13N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W70V6I2OMY, chemically known as 2-propynylamine, n-benzyl-n-methyl-, hydrochloride but more generally known as pargyline hydrochloride, which bears US NIH Compound Identifier 4688. European Medicines Agency schedules Pargyline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03653MIG.

Most nations, for tariff and trade purposes, schedule pargyline hydrochloride under HS 29214900 and SITC 51454. As of Q4 2014, PARGYLINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Pargyline hydrochloride bears US NLM identifiers UMLS ID C0282289 and NCI Concept Code C66323. SMILES: CN(CC#C)CC1CCCCC1.CL.

UNSPSC 51431612 Pargyline hydrochloride is a Commodity code identifying a specific pharmaceutical active ingredient, but state and local government procurement activity under this code shows minimal direct solicitation for pargyline alone. Instead, the recent opportunities tagged to this code reflect broader pharmaceutical procurement patterns: state and local buyers are acquiring emergency medications, generic multi-source pharmaceuticals, and prescription management services through consolidated purchasing vehicles and direct-to-manufacturer programs. The City of Tampa's sealed-bid procurement for Advanced Life Support Medications (solicitation 26P00188, due April 8, 2026) exemplifies how municipalities source emergency drugs for fire rescue operations, with firm pricing, nine-month minimum expiration dates, and expedited delivery within ten days. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products (due March 26, 2026) illustrates multi-state aggregated purchasing across state and local facilities, requiring vendors to meet cGMP and DSCSA compliance, maintain relationships with authorized wholesalers, and offer flexible pricing models. The Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescriptions signals state interest in disintermediated pharmacy supply chains that bypass traditional pharmacy benefit managers and group purchasing organizations.

Geographic activity concentrates in Florida, Minnesota, Oregon, and Texas, with cooperative purchasing vehicles extending reach across multiple jurisdictions. Issuing bodies include municipalities (Tampa), state health agencies (Texas HHS), state procurement offices (Minnesota Department of Administration), and multistate cooperative alliances (MMCAP). The Tampa opportunity carries a $40,000 estimated contract value with a Small Local Business Enterprise sheltered-market designation offering a 5 percent bid discount; the MMCAP RFP requires a 3 percent administrative fee on all purchases and imposes performance penalties of $200 to $1,500 per violation. No award value or budget is disclosed for the Texas RFI, which functions as an exploratory information-gathering phase prior to formal RFP issuance. The code itself does not appear to drive standalone procurement; instead, pargyline hydrochloride would be sourced as part of broader emergency medication, generic drug, or therapeutic pharmacy initiatives rather than as a line item in isolation.